[How should hormone therapy for castration-resistant prostate cancer be continued?]

Spahn, M; Krebs, M (2012). [How should hormone therapy for castration-resistant prostate cancer be continued?]. Urologe, 51(1), pp. 15-19. Berlin: Springer 10.1007/s00120-011-2738-9

Preview

Text s00120-011-2738-9.pdf - Published Version Available under License Publisher holds Copyright. Download (292kB) | Preview

After an average of 18-36 months under androgen suppression therapy by surgical castration, LHRH, and steroidal or non-steroidal antiandrogens, almost all patients with metastatic prostate cancer show PSA progression as a sign of androgen-independent but still androgen-sensitive tumor growth. Our understanding and the treatment of such castration-resistant prostate cancer has changed markedly. The introduction of new drugs like abiraterone and MDV3100 has shown that prostate cancer progression even in the"hormone-refractory" stage is driven by androgen receptor signaling. Based on this information the question of whether androgen deprivation therapy in castration-resistant prostate cancer should be continued or not is still of relevance. This review gives a critical overview of the literature and current guideline recommendations.

Interest & Impact

Downloads

58 since deposited on 04 Oct 2013
30 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item